Zhizhuang Zhao to Humans
This is a "connection" page, showing publications Zhizhuang Zhao has written about Humans.
Connection Strength
0.679
-
Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera. PLoS One. 2020; 15(6):e0232801.
Score: 0.040
-
Loss of tyrosine phosphatase SHP2 activity promotes growth of colorectal carcinoma HCT-116 cells. Signal Transduct Target Ther. 2020 05 29; 5(1):83.
Score: 0.040
-
Finding new lanes: Chimeric antigen receptor (CAR) T-cells for myeloid leukemia. Cancer Rep (Hoboken). 2020 04; 3(2):e1222.
Score: 0.039
-
Specific dephosphorylation of Janus Kinase 2 by protein tyrosine phosphatases. Proteomics. 2015 Jan; 15(1):68-76.
Score: 0.027
-
Generation and characterization of a JAK2V617F-containing erythroleukemia cell line. PLoS One. 2014; 9(7):e99017.
Score: 0.027
-
Elevated levels of mast cells are involved in pruritus associated with polycythemia vera in JAK2V617F transgenic mice. J Immunol. 2014 Jul 15; 193(2):477-84.
Score: 0.026
-
SU11652 Inhibits tyrosine kinase activity of FLT3 and growth of MV-4-11 cells. J Hematol Oncol. 2012 Dec 06; 5:72.
Score: 0.024
-
Generation and characterization of a highly effective protein substrate for analysis of FLT3 activity. J Hematol Oncol. 2012 Jul 16; 5:39.
Score: 0.023
-
Development of a highly sensitive method for detection of JAK2V617F. J Hematol Oncol. 2011 Oct 10; 4:40.
Score: 0.022
-
Tea contains potent inhibitors of tyrosine phosphatase PTP1B. Biochem Biophys Res Commun. 2011 Apr 01; 407(1):98-102.
Score: 0.021
-
Relevance of JAK2V617F positivity to hematological diseases--survey of samples from a clinical genetics laboratory. J Hematol Oncol. 2011 Jan 14; 4:4.
Score: 0.021
-
Identification of a variant form of tyrosine phosphatase LYP. BMC Mol Biol. 2010 Nov 02; 11:78.
Score: 0.021
-
Characterization of a highly effective protein substrate for analysis of JAK2(V617F) Activity. Exp Hematol. 2007 Nov; 35(11):1624-32.
Score: 0.017
-
Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J Biol Chem. 2007 Feb 09; 282(6):3428-32.
Score: 0.016
-
JAK2(V617F): Prevalence in a large Chinese hospital population. Blood. 2007 Jan 01; 109(1):339-42.
Score: 0.015
-
Antagonism or synergism. Role of tyrosine phosphatases SHP-1 and SHP-2 in growth factor signaling. J Biol Chem. 2006 Aug 04; 281(31):21878-21883.
Score: 0.015
-
Role of tyrosine kinases and phosphatases in polycythemia vera. Semin Hematol. 2005 Oct; 42(4):221-9.
Score: 0.014
-
Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005 Jun 17; 280(24):22788-92.
Score: 0.014
-
PTP-MEG2 is activated in polycythemia vera erythroid progenitor cells and is required for growth and expansion of erythroid cells. Blood. 2003 Dec 15; 102(13):4354-60.
Score: 0.012
-
Identification of a variant form of PZR lacking immunoreceptor tyrosine-based inhibitory motifs. Biochem Biophys Res Commun. 2003 Apr 18; 303(4):1028-33.
Score: 0.012
-
Specific interaction of protein tyrosine phosphatase-MEG2 with phosphatidylserine. J Biol Chem. 2003 Jun 20; 278(25):22609-14.
Score: 0.012
-
Bioinformatics analyses of combined databases identify shared differentially expressed genes in cancer and autoimmune disease. J Transl Med. 2023 02 10; 21(1):109.
Score: 0.012
-
Efficacy of SCF drug conjugate targeting c-KIT in gastrointestinal stromal tumor. BMC Med. 2022 08 24; 20(1):257.
Score: 0.012
-
SPAP2, an Ig family receptor containing both ITIMs and ITAMs. Biochem Biophys Res Commun. 2002 May 10; 293(3):1037-46.
Score: 0.011
-
Tyrosine phosphatases SHP-1 and SHP-2 are associated with distinct tyrosine-phosphorylated proteins. Exp Cell Res. 2002 Jan 01; 272(1):75-83.
Score: 0.011
-
Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression. Microb Cell Fact. 2021 Mar 10; 20(1):67.
Score: 0.011
-
Association of PTPN22-C1858T Polymorphism With Susceptibility to Mycobacterium tuberculosis and Mycobacterium leprae Infection: A Meta-Analysis. Front Immunol. 2021; 12:592841.
Score: 0.011
-
miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2. JCI Insight. 2020 01 16; 5(1).
Score: 0.010
-
Proapoptotic Mitochondrial Carrier Homolog Protein PSAP Mediates Death Receptor 6 Induced Apoptosis. J Alzheimers Dis. 2020; 74(4):1097-1106.
Score: 0.010
-
CRISPR/Cas9 Knockout of Bak Mediates Bax Translocation to Mitochondria in response to TNFa/CHX-induced Apoptosis. Biomed Res Int. 2019; 2019:9071297.
Score: 0.010
-
ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis. Leukemia. 2019 05; 33(5):1287-1291.
Score: 0.009
-
Nanoscale photoacoustic tomography for label-free super-resolution imaging: simulation study. J Biomed Opt. 2018 11; 23(11):1-10.
Score: 0.009
-
Phenotype risk scores identify patients with unrecognized Mendelian disease patterns. Science. 2018 03 16; 359(6381):1233-1239.
Score: 0.009
-
Efficacy of ALK5 inhibition in myelofibrosis. JCI Insight. 2017 04 06; 2(7):e90932.
Score: 0.008
-
Plasma exosome microRNAs are indicative of breast cancer. Breast Cancer Res. 2016 09 08; 18(1):90.
Score: 0.008
-
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016; 12(1):1-222.
Score: 0.007
-
Erlotinib is not effective in patients with JAK2V617F-positive polycythemia vera. Ann Hematol. 2015 Apr; 94(4):717-9.
Score: 0.007
-
CD169? macrophages provide a niche promoting erythropoiesis under homeostasis and stress. Nat Med. 2013 Apr; 19(4):429-36.
Score: 0.006
-
RBPJ mutations identified in two families affected by Adams-Oliver syndrome. Am J Hum Genet. 2012 Aug 10; 91(2):391-5.
Score: 0.006
-
The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis. Am J Pathol. 2012 Sep; 181(3):858-65.
Score: 0.006
-
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012 Apr; 8(4):445-544.
Score: 0.006
-
Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth in breast cancer. Breast Cancer Res. 2012 Mar 06; 14(2):R38.
Score: 0.006
-
A46, a benzothiophene-derived compound, suppresses Jak2-mediated pathologic cell growth. Exp Hematol. 2012 Jan; 40(1):22-34.
Score: 0.006
-
Crystal structure of human protein tyrosine phosphatase SHP-1 in the open conformation. J Cell Biochem. 2011 Aug; 112(8):2062-71.
Score: 0.005
-
Protein-tyrosine phosphatase PTPN9 negatively regulates ErbB2 and epidermal growth factor receptor signaling in breast cancer cells. J Biol Chem. 2010 May 14; 285(20):14861-14870.
Score: 0.005
-
Cell density-dependent regulation of p73 in breast cancer cells. Int J Oncol. 2009 Dec; 35(6):1429-34.
Score: 0.005
-
Detection of the JAK2V617F mutation by asymmetric PCR and melt curve analysis. Cancer Biomark. 2007; 3(6):315-24.
Score: 0.004
-
SHP-1 dephosphorylates 3BP2 and potentially downregulates 3BP2-mediated T cell antigen receptor signaling. FEBS J. 2006 May; 273(10):2195-205.
Score: 0.004
-
PKHD1 protein encoded by the gene for autosomal recessive polycystic kidney disease associates with basal bodies and primary cilia in renal epithelial cells. Proc Natl Acad Sci U S A. 2004 Feb 24; 101(8):2311-6.
Score: 0.003
-
Crystal structure of human protein-tyrosine phosphatase SHP-1. J Biol Chem. 2003 Feb 21; 278(8):6516-20.
Score: 0.003
-
Substrate specificity of protein tyrosine phosphatase: differential behavior of SHP-1 and SHP-2 towards signal regulation protein SIRPalpha1. J Cell Biochem. 2002; 84(4):840-6.
Score: 0.003